Aha!! This actually sounds like a conference call worthy of attendance.
Thx for your response Daly...
"...maybe he's dropping a subtle hint..."
Perhaps you are right, Joe.
But, with a year-end earnings call (and EOQ) next week, I just don't see how the topic would even arise in a lawyer-intro conference. At various times in the past couple of years, the BS phenom has intrigued some of the foremost players in PC research....including a host of curiosity seeker-types like myself. Why bring it up to hire a new barrister.
It defies logic...
"...MMM made it very clear that people are stressing bone scan too much..."
I missed the call, and can't find either transcript or audio reproduction...
How do you interpret this remark, Clem? Ernie? Hbomb? Bif?
...and why do you imagine this topic even came up in a call mostly designed to introduce the new EVP?
It makes no sense to me...
Those most inclined to place importance on the Cabo bone phenom were likely the least inclined to participate in such a call...at least from my perspective. If the science is intact, the BSR phenomenon lends to Cabo a distinctive "hallmark" sign of successful treatment uptake to the bone micro-environment, and if - as has been suggested by multiple researchers - this early clarification of bone response upon scan can be applied as a predictor of beneficial response - it could easily prove one of the more important finds in the history of cancerous disease progression to bone. Were MMM's remarks in response to a question, or was he spitballing? I'm at a loss...
In fact, I've been awonderin' "now why don't he write"...
Now - the message is painfully clear...
Yer access is based on scheduled penitentiary rules....
...and at the discretion of your guard, your warden, and your parole officer.
Even yer psychiatrist probly has some restrictions...
No worrries...you'll likely be out in 5 to 7, and then we can chat all you want.
Free speech is a gas, ain't it?
Cya downstream, cubicle boy...
Hey Joe...just a friendly heads-up - OPTT looks explosive downstream.
I have a very small position, bought weeks ago. waiting on a pullback that simply hasn't taken place.
Big Aussie off-shore wave-power deal with Lockheed Martin announced this week.
Looks like long-term potential...lots of volume today. Watch...
Just off the wire...looks like this young lawyer nearly as vested as I am. LOL
"Jeffrey Hessekiel, Exelixis's EVP and General Counsel, just received 230,000 options from the company. The strike price of the options received was $7.27, and these expire on February 09, 2021. Hessekiel now owns at least 230,000 options on the company."
My further apologies, Jamer...I meant no detritus... I'm long and wish EXEL all the best.
I was - only yesterday - compelled to seek legal counsel in a community riparian rights dispute.
I was put on hold pending credit update and analysis. When it comes to lawyers, I'm with Don Henley: Let God sort 'em out.
I gotta admit, considering the content of yesterday's discussion, I broke a grin when a saw that EXEL hired a new lawyer to assist EXEL's transition to a global concept:
“Jeff’s appointment comes at an important time for Exelixis, as we strive to fully maximize the opportunity for cabozantinib and further develop cabozantinib into a major oncology product,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “His broad and successful legal experience, particularly with regard to pharmaceutical marketing and commercialization, makes him well prepared to guide us through the complex issues that arise as we continue our transformation into a global commercial organization.”
My apologies, but this sorta stuff is funny to me...
This is good news, OOG. The ante-ups of institutions and the options trafficking over the next couple months bode well for us all. I think the SP strength that we all recognized in the couple months prior to the offering says it all.
"There is no such requirement and companies do sit on trial results."
To which I'd like to add...
If you choose to invest in biotech, expect to occasionally get thrown to the lions.
It happens...and there is most often no recourse than to buck up and bite the bullet.
Were you guys on-board this stock when the 6 AE5's were announced?
Here's from the OncLive reporting:
"Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO’s annual meeting. The fatalities had not been reported with the cabozantinib data at the May 18 pre-ASCO press briefing. Shares of the drug’s manufacturer, Exelixis, fell 20% as investors reacted to the news. The fatal cabozantinib-related adverse events affected patients across multiple tumor sites, including breast cancer (respiratory compromise), non–small cell lung cancer (NSCLC, hemorrhage), ovarian cancer (enterocutaneous perforation, intestinal perforation), pancreatic cancer (gastrointestinal hemorrhage), and castrate-resistant prostate cancer (CRPC, unexplained). The 6 deaths comprised 1% of the 490 patients treated in the study."
Perhaps in an attempt to soften the blow, Dr Nicolas Vogelzang chose to quote Shakespeare:
"Diseases desperate grown, by desperate appliance are relieved, or not at all."
Of course, it was later revealed that the AE profile of Cabo was in-line with other TKI's, but not until the damage had been done for current shareholders. How might your understanding of the rules of disclosure apply to this witholding? Making a case for appropriate disclosure should necessarily contain the ingredients of timeliness, relative pertinence, and with complete acknowledge of factual basis...should it not? Personally, I felt blindsided by this event, and to this day feel that it was handled poorly.
Ernie, I hate to bring a sore point to attention...particularly with you. But I understand you felt you (and all shareholders) were burned badly in the MEDX takeout. It always smelled to me as if a sweetheart deal had been cut to exclude shareholder gain. BMY departnered XL-184 after paying a great deal of the P2RDT costs, and also the P3 EXAM in MTC Would you care to share you current thoughts on the prospect of an EXEL-BMY sweetheart deal? Any chance you see us getting blindsided by a back-door deal?...perhaps set up long ago, just in the event Cabo hit it's intended top-line numbers?
Whoch to me, looks like could indeed happen...
"...it will be a material event and treated as such...."
...and not hidden to a future revealing by a CT order?
I'm not entirely familiar with these types of issues, but it's interesting to note that EXEL executed 2 CT filings this past week. It might be worthy of research...
CHMP positive opinion was announced on 12/19/13, and a typical timeline might be considered to be 1 to 3 months for EMEA response, but their agenda is of their own design. That said, there is also the possibility that Cabo's orphan status may hasten the process a bit...though I doubt it. With the NPU program already in place, there is really no unmet need to consider. Patience...
Isn't there always a woman to blame?
I believe Hoyt passed on, likely a coronary thing...
He was a fairly large feller, and undoubtedly vulnerable to the weaknesses that seem to haunt those of creative aspect. Sleep is often evasive, life's just too dern short.
Published online in the European Journal of Cancer 13 Jan 2014, D Lorente and JS DeBono
"AR blockade can increase c-Met signalling, inducing EMT and stem-cell like phenotypes. C-Met has been postulated to be the main target for cabozantinib, although this remains controversial. Cabozantinib (XL184) also inhibits vascular endothelial growth factor receptor (VEGFR), RET, platelet derived growth factor receptor (PDGFR), KIT, AXL, and FLT3 receptor tyrosine kinases ; this agent improves survival from medullary thyroid carcinoma . A randomised discontinuation phase II trial in patients with metastatic CRPC was halted after a first interim analysis due to significant benefit in the treatment arm, with a median PFS of 23.9 versus 5.9weeks (HR 0.12, p
Hey Joe...I like it when you show up.
Stick around for a spell, bring us some luck. I agree. Xofigo seems like a cumbersome ride to me...
That said...My 2014 is off to a real western start. My favored gelding has lamed up with what I suspect is chronic ringbone. My back-up mare is quarantined with the strangles. My current third is barely halter-broke, and never yet been rode - only saddled a time or two. My century-roping partner just got the long-faced news following a colonoscopy...and we're waiting on follow-up labworx. Got my big-box Gibson in my lap working thru Hoyt Axton's "Bony Fingers"...Know it? Great western blues...
Well the rains coming down and the roof won't hold'er...
And I lost my job & the kids are getting older...
Truck won't start and the nights are getting colder...
...maybe things li'l get a little better in the morning...
Maybe things'll get a little better.
Work yer fingers to the bone...what do you get...
Bony fingers....bony fingers...
Thanks, Bif. I look forward to a time when you are carefully And concisely explaining to this MB that Xofigo use has diminished...and become essentially extinct due to the fact that combinations of Abi, Xtandi and Cabo have long since prevented the onset of painful bone mets. Oh Mama...
As I understand the myelo-suppressive AE profile of Xofigo, there are limitations of treatment for this radio-label that won't overlap with the AE profile of Cabo...ie. if bone marrow dysfunction becomes unmanageable w/ Xofigo treatment, yet bone pain returns or persists - Cabo might be considered as alternate treatment with no continuing dysfunctional impact on bone marrow function. Am I seeing this correctly?